

# Cheol Moon

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8302315/cheol-moon-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32  
papers

829  
citations

16  
h-index

28  
g-index

32  
ext. papers

952  
ext. citations

6.2  
avg, IF

3.84  
L-index

#	Paper	IF	Citations
32	BSA/Silver Nanoparticle-Loaded Hydrogel Film for Local Photothermal Treatment of Skin Cancer. <i>Pharmaceutical Research</i> , <b>2021</b> , 38, 873-883	4.5	3
31	Drug Delivery Strategies for Enhancing the Therapeutic Efficacy of Toxin-Derived Anti-Diabetic Peptides. <i>Toxins</i> , <b>2020</b> , 12,	4.9	4
30	Development and characterization of a superabsorbing hydrogel film containing var. root bark and pullulan for skin wound healing. <i>Saudi Pharmaceutical Journal</i> , <b>2020</b> , 28, 791-802	4.4	5
29	ICG-Loaded PEGylated BSA-Silver Nanoparticles for Effective Photothermal Cancer Therapy. <i>International Journal of Nanomedicine</i> , <b>2020</b> , 15, 5459-5471	7.3	23
28	Multivariate Statistical Optimization of Tablet Formulations Incorporating High Doses of a Dry Herbal Extract. <i>Pharmaceutics</i> , <b>2019</b> , 11,	6.4	4
27	Genetic engineering and characterisation of chlorotoxin-fused gelonin for enhanced glioblastoma therapy. <i>Journal of Drug Targeting</i> , <b>2019</b> , 27, 950-958	5.4	10
26	Pharmaceutical challenges and perspectives in developing ophthalmic drug formulations. <i>Journal of Pharmaceutical Investigation</i> , <b>2019</b> , 49, 215-228	6.3	21
25	Mesoporous Pravastatin Solid Dispersion Granules Incorporable Into Orally Disintegrating Tablets. <i>Journal of Pharmaceutical Sciences</i> , <b>2018</b> , 107, 1886-1895	3.9	4
24	Cell-penetrating peptide-based non-invasive topical delivery systems. <i>Journal of Pharmaceutical Investigation</i> , <b>2018</b> , 48, 77-87	6.3	17
23	Tandem-multimeric F3-gelonin fusion toxins for enhanced anti-cancer activity for prostate cancer treatment. <i>International Journal of Pharmaceutics</i> , <b>2017</b> , 524, 101-110	6.5	11
22	Heparin-Regulated Prodrug-Type Macromolecular Theranostic Systems for Cancer Therapy. <i>Nanotheranostics</i> , <b>2017</b> , 1, 114-130	5.6	8
21	Development of Solid Self-Emulsifying Formulation for Improving the Oral Bioavailability of Erlotinib. <i>AAPS PharmSciTech</i> , <b>2016</b> , 17, 466-73	3.9	55
20	Nose-to-brain delivery of macromolecules mediated by cell-penetrating peptides. <i>Acta Pharmaceutica Sinica B</i> , <b>2016</b> , 6, 352-8	15.5	47
19	Rationale and strategies for formulation development of oral fixed dose combination drug products. <i>Journal of Pharmaceutical Investigation</i> , <b>2016</b> , 46, 615-631	6.3	14
18	Preparation and Characterization of Gelonin-Melittin Fusion Biotoxin for Synergistically Enhanced Anti-Tumor Activity. <i>Pharmaceutical Research</i> , <b>2016</b> , 33, 2218-2228	4.5	17
17	Improved tumor targeting and antitumor activity of camptothecin loaded solid lipid nanoparticles by preinjection of blank solid lipid nanoparticles. <i>Biomedicine and Pharmacotherapy</i> , <b>2016</b> , 80, 162-172	7.5	18
16	Employing an optimized spray-drying process to produce ezetimibe tablets with an improved dissolution profile. <i>Journal of Pharmaceutical Investigation</i> , <b>2016</b> , 46, 583-592	6.3	13

15	Lichen Secondary Metabolite, Physciosporin, Inhibits Lung Cancer Cell Motility. <i>PLoS ONE</i> , <b>2015</b> , 10, e0137889	16
14	Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy. <i>Journal of Controlled Release</i> , <b>2014</b> , 194, 197-210	11.7 37
13	Lichen secondary metabolites in <i>Flavocetraria cucullata</i> exhibit anti-cancer effects on human cancer cells through the induction of apoptosis and suppression of tumorigenic potentials. <i>PLoS ONE</i> , <b>2014</b> , 9, e111575	3.7 47
12	Preparation of microcapsules with the evaluation of physicochemical properties and molecular interaction. <i>Archives of Pharmacal Research</i> , <b>2014</b> , 37, 1570-7	6.1 7
11	Cell-penetrating peptide-mediated topical delivery of biomacromolecular drugs. <i>Current Pharmaceutical Biotechnology</i> , <b>2014</b> , 15, 231-9	2.6 11
10	Immobilized thermolysin for highly efficient production of low-molecular-weight protamine--an attractive cell-penetrating peptide for macromolecular drug delivery applications. <i>Journal of Biomedical Materials Research - Part A</i> , <b>2012</b> , 100, 211-9	5.4 10
9	Formulation and in vitro evaluation of transdermal drug delivery system for donepezil. <i>Journal of Pharmaceutical Investigation</i> , <b>2012</b> , 42, 1-7	6.3 16
8	Influence of formulation variables in transdermal drug delivery system containing zolmitriptan. <i>International Journal of Pharmaceutics</i> , <b>2011</b> , 419, 209-14	6.5 27
7	ATTEMPTS system: a macromolecular prodrug strategy for cancer drug delivery. <i>Current Pharmaceutical Design</i> , <b>2010</b> , 16, 2369-76	3.3 33
6	Synthetic Skin-Permeable Proteins Enabling Needleless Immunization. <i>Angewandte Chemie</i> , <b>2010</b> , 122, 2784-2787	3.6 6
5	Synthetic skin-permeable proteins enabling needleless immunization. <i>Angewandte Chemie - International Edition</i> , <b>2010</b> , 49, 2724-7	16.4 45
4	L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL). <i>Journal of Controlled Release</i> , <b>2009</b> , 139, 182-9	11.7 92
3	A novel polyrotaxane-based intracellular delivery system for camptothecin: in vitro feasibility evaluation. <i>Journal of Biomedical Materials Research - Part A</i> , <b>2008</b> , 84, 238-46	5.4 26
2	In vitro assessment of a novel polyrotaxane-based drug delivery system integrated with a cell-penetrating peptide. <i>Journal of Controlled Release</i> , <b>2007</b> , 124, 43-50	11.7 79
1	Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. <i>FASEB Journal</i> , <b>2005</b> , 19, 1555-7	0.9 103